CVM: Cel-Sci Corp. announced on Thursday that its partner in Taiwan, Orient Europharma, has completed the necessary final steps before patient enrollment into the Multikine Phase III trial can commence.

According to a CVM press release, the Multikine that will be used for the Taiwan portion of the trial was sent this week, and Orient plans to add an additional six trial sites over time.

Shares of CVM have remained trading for right around fifty cents, not a bad entry point - in my opinion - for those looking at the blockbuster potential of Multikine should it make it through Phase III trials unscathed.

Another press release this week discussed Multikine's potential choloesterol-reducing properties, as well, although an investment here is an investment in Multikine, plain and simple.

It could be a little while before CVM starts to inch back towards the dollar mark, but it's one to keep an eye on as a potential cancer immunotherapy blockbuster.

Disclosure: Long CVM.

Add a Comment